Apellis Pharmaceuticals (APLS) to Release Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) will likely be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.37) per share and revenue of $197.92 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Apellis Pharmaceuticals Trading Down 0.2 %

APLS opened at $27.40 on Tuesday. The firm has a market capitalization of $3.41 billion, a P/E ratio of -13.50 and a beta of 0.96. The firm’s 50 day moving average is $31.05 and its 200-day moving average is $32.03. Apellis Pharmaceuticals has a 52-week low of $24.34 and a 52-week high of $71.90. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Wall Street Analyst Weigh In

APLS has been the subject of a number of research reports. Morgan Stanley initiated coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price objective for the company. Robert W. Baird reduced their price target on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. Wells Fargo & Company dropped their price target on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $26.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, January 29th. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Insider Buying and Selling

In other news, CAO James George Chopas sold 1,096 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $33,351.28. Following the completion of the sale, the chief accounting officer now owns 48,138 shares of the company’s stock, valued at approximately $1,464,839.34. This represents a 2.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Timothy Eugene Sullivan sold 1,730 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $51,830.80. Following the completion of the sale, the chief financial officer now directly owns 86,370 shares of the company’s stock, valued at approximately $2,587,645.20. The trade was a 1.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,365 shares of company stock worth $1,810,479 in the last ninety days. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).